CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells

Human Gene Therapy

Volumn 21, Issue 12, 2010, Pages 1697-1706

  Kim, Yun Sun ^a   Kim, Yeon Jeong ^a   Lee, Jung Mi ^a   Han, Seung Hee ^a   Ko, Hyun Jeong ^a,b   Park, Hae Jung ^c   Pereboev, Alexander ^d   Nguyen, Huan H ^c,e   Kang, Chang Yuil ^a,f  

^a Seoul National University   (South Korea)

^b Kangwon National University   (South Korea)

^c International Vaccine Institute   (South Korea)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADENOVIRUS VECTOR; CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND; DENDRITIC CELL VACCINE; GEMCITABINE; PROTEIN CFM40L; PROTEIN E6; PROTEIN E7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CELL ACTIVATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; GENE TARGETING; GENE TRANSFER; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD40; B-LYMPHOCYTES; CANCER VACCINES; CD40 LIGAND; CLONING, MOLECULAR; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN;

ADENOVIRIDAE; COXSACKIEVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MURINAE;

EID: 78650153340     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.202     Document Type: Article

References (33)

1. Appledorn, D.M., Patial, S., McBride, A., Godbehere, S., Van Rooijen, N., Parameswaran, N., and Amalfitano, A. (2008). Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181, 2134-2144.
2. Bleharski, J.R., Niazi, K.R., Sieling, P.A., Cheng, G., and Modlin, R.L. (2001). Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J. Immunol. 167, 3174-3181. (Pubitemid 32852556)
3. Chung, Y., Kim, B.S., Kim, Y.J., Ko, H.J., Ko, S.Y., Kim, D.H., and Kang, C.Y. (2006). CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res. 66, 6843-6850. (Pubitemid 44085645)
4. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J.V., Steinman, R.M., and Nussenzweig, M.C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779. (Pubitemid 32983013)
5. \+ cells. Gene Ther. 15, 298-308. (Pubitemid 351223466)
6. Jenne, L., Schuler, G., and Steinkasserer, A. (2001). Viral vectors for dendritic cell-based immunotherapy. Trends Immunol. 22, 102-107. (Pubitemid 32667530)
7. Jin, H.T., Youn, J.I., Kim, H.J., Lee, J.B., Ha, S.J., Koh, J.S., and Sung, Y.C. (2005). Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 sub-unit and the combination with farnesyltransferase inhibitor. Hum. Gene Ther. 16, 328-338.
8. Kim, Y.J., Ko, H.J., Kim, Y.S., Kim, D.H., Kang, S., Kim, J.M., Chung, Y., and Kang, C.Y. (2008). a-Galactosylceramide-loaded, antigen-expressing B cells prime a wide spectrum of antitumor immunity. Int. J. Cancer 122, 2774-2783. (Pubitemid 351631380)
9. Kim, Y.S., Ko, H.J., Kim, Y.J., Han, S.H., Lee, J.M., Chang, W.S., Jin, H.T., Sung, Y.C., and Kang, C.Y. (2007). B cells transduced with HPV16 E6/E7-expressing adenoviral vector can efficiently induce CTL-dependent anti-tumor immunity. Immune Network 7, 109-116.
10. Kirk, C.J., and Mule, J.J. (2000). Gene-modified dendritic cells for use in tumor vaccines. Hum. Gene Ther. 11, 797-806. (Pubitemid 30202471)
11. Ko, H.J., Kim, Y.J., Kim, Y.S., Chang, W.S., Ko, S.Y., Chang, S.Y., Sakaguchi, S., and Kang, C.Y. (2007). A combination of che-moimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477-7486. (Pubitemid 47206577)
12. Kurts, C., Sutherland, R.M., Davey, G., Li, M., Lew, A.M., Blanas, E., Carbone, F.R., Miller, J.F., and Heath, W.R. (1999). CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. U.S.A. 96, 12703-12707. (Pubitemid 29513566)
13. \+ monocytes cultured under serum-free conditions. Blood 99, 600-608. (Pubitemid 34533098)
14. Mehrotra, S., Chhabra, A., Chakraborty, A., Chattopadhyay, S., Slowik, M., Stevens, R., Zengou, R., Mathias, C., Butterfield, L.H., Dorsky, D.I., Economou, J.S., Mukherji, B., and Chak-raborty, N.G. (2004). Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113, 472-481. (Pubitemid 39593366)
15. Mende, I., and Engleman, E.G. (2005). Breaking tolerance to tumors with dendritic cell-based immunotherapy. Ann. N. Y. Acad. Sci. 1058, 96-104.
16. Morris, A.E., Remmele, R.L., Jr., Klinke, R., Macduff, B.M., Fanslow, W.C., and Armitage, R.J. (1999). Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J. Biol. Chem. 274, 418-423. (Pubitemid 29035077)
17. Nakamura, M., Iwahashi, M., Nakamori, M., Ueda, K., Ojima, T., Naka, T., Ishida, K., and Yamaue, H. (2005). Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: Comparison with immuno-dominant peptide-pulsed DCs. Oncology 68, 163-170. (Pubitemid 41158972)
18. Palucka, A.K., Ueno, H., Fay, J.W., and Banchereau, J. (2007). Taming cancer by inducing immunity via dendritic cells. Immunol. Rev. 220, 129-150. (Pubitemid 350045575)
19. Penichet, M.L., Challita, P.M., Shin, S.U., Sampogna, S.L., Rosenblatt, J.D., and Morrison, S.L. (1999). In vivo properties of three human HER2/neu-expressing murine cell lines in im-munocompetent mice. Lab. Anim. Sci. 49, 179-188. (Pubitemid 29207285)
20. Pereboev, A.V., Asiedu, C.K., Kawakami, Y., Dong, S.S., Black-well, J.L., Kashentseva, E.A., Triozzi, P.L., Aldrich, W.A., Curiel, D.T., Thomas, J.M., and Dmitriev, I.P. (2002). Coxsackievirus- adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9, 1189-1193. (Pubitemid 34993942)
21. Pereboev, A.V., Nagle, J.M., Shakhmatov, M.A., Triozzi, P.L., Matthews, Q.L., Kawakami, Y., Curiel, D.T., and Blackwell, J.L. (2004). Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol. Ther. 9, 712-720. (Pubitemid 38660424)
22. Rebel, V.I., Hartnett, S., Denham, J., Chan, M., Finberg, R., and Sieff, C.A. (2000). Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells 18, 176-182. (Pubitemid 30341665)
23. Rethi, B., Gogolak, P., Szatmari, I., Veres, A., Erdos, E., Nagy, L., Rajnavolgyi, E., Terhorst, C., and Lanyi, A. (2006). SLAM/ SLAM interactions inhibit CD40-induced production of inflammatory cytokines in monocyte-derived dendritic cells. Blood 107, 2821-2829.
24. Ribas, A., Butterfield, L.H., McBride, W.H., Jilani, S.M., Bui, L.A., Vollmer, C.M., Lau, R., Dissette, V.B., Hu, B., Chen, A.Y., Glaspy, J.A., and Economou, J.S. (1997). Genetic immunization for the melanoma antigen MART-1/Melan-A using recombi-nant adenovirus-transduced murine dendritic cells. Cancer Res. 57, 2865-2869. (Pubitemid 27315029)
25. Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., Gribben, J.G., and Nadler, L.M. (1997). CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100, 2757-2765. (Pubitemid 28007544)
26. Schultze, J.L., Grabbe, S., and Von Bergwelt-Baildon, M.S. (2004). DCs and CD40-activated B cells: Current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25, 659-664. (Pubitemid 39457979)
27. Spiotto, M.T., Fu, Y.X., and Schreiber, H. (2003). Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15, 725-730. (Pubitemid 37434082)
28. Sun, J.B., Flach, C.F., Czerkinsky, C., and Holmgren, J. (2008). B lymphocytes promote expansion of regulatory T cells in oral tolerance: Powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 181, 8278-8287.
29. Tillman, B.W., De Gruijl, T.D., Luykx-De Bakker, S.A., Scheper, R.J., Pinedo, H.M., Curiel, T.J., Gerritsen, W.R., and Curiel, D.T. (1999). Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162, 6378-6383. (Pubitemid 29309357)
30. Tillman, B.W., Hayes, T.L., Degruijl, T.D., Douglas, J.T., and Curiel, D.T. (2000). Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60, 5456-5463.
31. Whittington, P.J., Radkevich-Brown, O., Jacob, J.B., Jones, R.F., Weise, A.M., and Wei, W.Z. (2009). Her-2 DNA versus cell vaccine: Immunogenicity and anti-tumor activity. Cancer Immunol. Immunother. 58, 759-767.
32. Xia, D., Moyana, T., and Xiang, J. (2006). Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. 16, 241-259.
33. Xu, H., Zhang, Y., Hua, Y., Chen, T., Wang, H., and Wu, W. (2007). IL-12 p35 silenced dendritic cells modulate immune responses by blocking IL-12 signaling through JAK-STAT pathway in T lymphocytes. Biochem. Biophys. Res. Commun. 353, 812-816. (Pubitemid 46048744)